1Payne C, Zhang X, Shahri N, et al. Evaluation of potential drug-drug interactions with baricitinib. Ann Rheum Dis. 2015;74(suppl 2):1063. European League Against Rheumatism abstract AB0492. https://doi.org/10.1136/annrheumdis-2015-eular.1627
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3Zhao X, Payne C, Wang F, Cui Y. THU0199 pharmacokinetics, safety and tolerability of single- and multiple-dose once-daily baricitinib in Chinese healthy volunteers – a randomized placebo-controlled study. Ann Rheum Dis. 2019;78(suppl 2);378. https://ard.bmj.com/content/78/Suppl_2/378.1
4Posada MM, Cannady EA, Payne CD, et al. Prediction of transporter-mediated drug-drug interactions for baricitinib. Clin Transl Sci. 2017;10(6):509-519. https://dx.doi.org/10.1111/cts.12486
5Dupixent: EPAR - product information. European Medicines Agency. Updated July 2, 2020. Accessed September 10, 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent
6Davis JD, Bansal A, Hassman D, et al. Evaluation of potential disease-mediated drug-drug interaction in patients with moderate-to-severe atopic dermatitis receiving dupilumab. Clin Pharmacol Ther. 2018;104(6):1146-1154. http://dx.doi.org/10.1002/cpt.1058